ArticleAnnals of surgical oncology2025
Robot-Assisted Versus Conventional Laparoscopic Radical Cystectomy in a Multicenter Cohort Study: A Propensity Score Matching Analysis.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRobot-assisted radical cystectomy (RARC) and laparoscopic radical cystectomy (LRC) are becoming increasingly prevalent. However, whether the two surgical procedures share the same oncologic outcomes remains controversial. PATIENTS AND
methodsA multicenter, retrospective study was conducted. Patients who underwent radical cystectomy for histologically confirmed bladder cancer at ten centers between 2012 and 2019 were enrolled. Data on baseline conditions, perioperative details, pathological results, and survival outcomes were collected. The primary outcome measures were overall survival (OS), recurrence-free survival (RFS), and cancer-specific survival (CSS). Propensity score matching was conducted to reduce the effects of bias and confounding variables, while multiple imputation was applied to address missing variables.
resultsA total of 2766 patients were enrolled, including 1291 LRC patients and 1475 RARC patients. After propensity score matching, a total of 753 pairs of patients were obtained. In the RARC group, organ-confined diseases were detected in 482 patients (64.0%). Lymph node metastasis was observed in 120 (15.9%) patients. In the LRC group, organ-confined diseases were detected in 521 (69.2%) patients, and 101 (13.4%) patients had lymph node metastasis. The median follow-up time was 47.6 months (33.4-63.4 months) for the RARC group and 45.6 months (23.1-70.8 months) for the LRC group. Survival analysis showed no statistically significant differences in OS (HR: 0.89, 95% CI: 0.72-1.10, p = 0.269), RFS (HR: 0.84, 95% CI: 0.69-1.01, p = 0.069), and CSS (HR: 0.86, 95% CI: 0.68-1.08, p = 0.196) between the two groups. Recurrent bladder cancer, T stage, and lymph node metastasis were identified as significant risk factors.
conclusionsThere were no statistically significant differences in oncologic outcomes between RARC and LRC.
Indexed as
Identifiers
40540221What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.